home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Events -> Courses and Workshops  
 

Overcoming Obstacles of the Canadian Drug Regulatory Landscape

 
  April 01, 2019  
     
 
Netzealous LLC DBA - Compliance4All, Online
2019-05-28


Overview:
Through this presentation, you will develop a comprehensive 

understanding of the Drug Approval Process and in parallel 

examine major misconceptions and misunderstandings.

Why should you Attend:
We will share insights and practical examples that facilitate a 

positive, proactive and transparent interaction with Health Canada, 

and provide strategies for avoiding obstacles and managing them 

efficiently should they occur.

Areas Covered in the Session:
Key strategic considerations at various stages of the Drug 

Development Process
The broader principals of the drug registration approach in Canada
Tips that will improve your efficiency and increase opportunities for 

successful market access

Who Will Benefit:
Pharma
Biotech Executives
Decision Makers
Study Sponsors

Event Fee: One Dial-in One Attendee Price: US $150.00

Contact Detail:
Compliance4All DBA NetZealous,
Phone: +1-800-447-9407
Email: compliance4all14@gmail.com
 
 
Organized by: Event Manager
Invited Speakers:
Speaker Profile:
Susanne Picard Founder and President of SPharm, is a sought-after expert on all aspects of the regulatory landscape. SPharm is a leading regulatory affairs consultancy headquartered in Canada that services clients around the globe.
 
Deadline for Abstracts: 2019-05-26
 
Registration: https://www.compliance4all.com/control/w_product/~product_id=502454LIVE?channel=molgen.org_May_2019_SEO
E-mail: compliance4all14@gmail.com
 
   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.